Nervous System News and Research

Latest Nervous System News and Research

FDA approves Neuralstem's IND for commencing a stem cell trial to treat Amyotrophic Lateral Sclerosis

Neuralstem, Inc. (NYSE Amex: CUR) today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to commence a Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells.

21 Sep 2009

King Pharmaceuticals achieves milestone: Announces commercial availability of EMBEDA

King Pharmaceuticals(R), Inc. (NYSE: KG) today announced a true milestone as it marks the first commercial availability for EMBEDA(TM) (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules, a long-acting Schedule II opioid analgesic for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

21 Sep 2009

Alcoholism may be dependent on IL-1 polymorphisms: Study

Cytokines are small proteins secreted by cells that serve as molecular messengers between cells. Pro-inflammatory cytokines - which function in the immune system - may be involved in alcohol dependence (AD). A study of three polymorphisms of the interleukin-1 gene complex (IL-1) and one of the tumor necrosis factor-alpha (TNFα) has found that IL-1 may directly contribute to AD among Spanish Caucasian males.

21 Sep 2009

Wyeth and Ambrx collaborate to produce the next generation of biologic drugs

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE) and Ambrx Inc. today announced the formation of a worldwide alliance to discover, develop, and commercialize protein drug candidates for three undisclosed targets in multiple therapeutic areas. The alliance will capitalize on Ambrx's recent breakthroughs in applying its protein medicinal chemistry platform to proteins produced in mammalian cells such as antibodies and antibody-toxin conjugates.

19 Sep 2009

Biopharmaceutical company announces initial public offering

Omeros Corporation today announced the launch of its initial public offering of 6.82 million shares of its common stock. Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system.

18 Sep 2009

Nasdaq Stock Market issues deficiency letter to Neurobiological Technologies

Neurobiological Technologies, Inc. (Nasdaq: NTII) ("NTI") announced today that, on September 15, 2009, it received a letter from The Nasdaq Stock Market indicating that the bid price of NTI's common stock has closed below $1.00 per share for 30 consecutive business days.

18 Sep 2009

Results from the BLOSSOM trial announced by Arena Pharmaceuticals

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) reported today positive, highly significant top-line results from the BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) trial.

18 Sep 2009

Rexahn to sign licensing and stock purchase agreements with Teva Pharmaceutical

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it has reached an agreement to close on its previously announced licensing and stock purchase agreements with Teva Pharmaceutical Industries Limited.

18 Sep 2009

FDA approves Valturna tablets for treating high blood pressure

The US Food and Drug Administration (FDA) has approved Valturna((R)) (aliskiren and valsartan) tablets, the first and only medicine to target two key points within the renin system, also known as the renin angiotensin aldosterone system (RAAS), an important regulator of blood pressure.

18 Sep 2009

KemPharm announces nomination of its second pipeline candidate

KemPharm, Inc. today announced the nomination of its second pipeline candidate, KP201, based on its proprietary ligand activated therapy (LAT) platform. KP201 is a new chemical entity (NCE) for the treatment of pain with the possibility of reduced abuse potential. KP201 joins lead candidate KP106, which is a novel prodrug candidate in development for ADHD.

16 Sep 2009

Phase 3 clinical study results of bazedoxifene released

Wyeth Pharmaceuticals, a division of Wyeth, announces findings from a placebo-controlled Phase 3 study of bazedoxifene 20 mg extended to five years, which indicated a significant reduction versus placebo in new vertebral fractures in postmenopausal women with osteoporosis.

15 Sep 2009

Alvine Pharmaceuticals raises funds for Phase 2a clinical trial of its lead compound ALV003

Alvine Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on developing and commercializing therapeutics for autoimmune/gastrointestinal diseases, today announced the closing of a $21.5 million extension of its Series A financing.

15 Sep 2009

Biocryst signs agreement with three partners to represent its anti-viral peramivir outside U.S.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has signed binding letters of intent with three partners who will exclusively represent BioCryst and its anti-viral peramivir for influenza stockpiling opportunities, as well as for marketing and distribution of peramivir for seasonal influenza upon local regulatory approval, within their territories outside the U.S.

15 Sep 2009

Extension study data on Fampridine-SR drug

Data from two long-term open-label extension studies of Fampridine-SR show that 86.0% of participants remained on therapy after a maximum treatment time of 15 months in study MS-F204EXT, and 69.5% remained on therapy after a maximum treatment time of 36 months in study MS-F203EXT.

15 Sep 2009

Alnylam and Medtronic announce pre-clinical research findings from their Huntington’s disease program

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Medtronic, Inc. (NYSE: MDT), the world’s leading developer of medical devices, announced today the presentation of new pre-clinical research findings from their Huntington’s disease program at the 2009 World Congress on Huntington’s Disease held September 12-15, 2009 in Vancouver, British Columbia.

15 Sep 2009

Neurologix to showcase novel gene transfer approach to Parkinson’s disease

Neurologix, Inc. (OTCBB: NRGX), a biotechnology company engaged in the development of innovative gene therapies for the brain and central nervous system, announced today that the company will showcase its novel gene transfer approach to Parkinson’s disease.

15 Sep 2009

Children with microcephaly should be screened for neurologic and cognitive problems, says guideline

A new guideline from the American Academy of Neurology, developed in full collaboration with the Child Neurology Society, finds that children with microcephaly that is, children whose head size is smaller than that of 97 percent of childrenare at risk of neurologic and cognitive problems and should be screened for these problems. The guideline is published in the September 15, 2009, issue of Neurology®, the medical journal of the American Academy of Neurology.

15 Sep 2009

Common pain cream could serve as cardiac-protectant during heart attack: Study

New research from the University of Cincinnati (UC) shows that a common, over-the-counter pain salve rubbed on the skin during a heart attack could serve as a cardiac-protectant, preventing or reducing damage to the heart while interventions are administered.

15 Sep 2009

Biotie Therapies commences clinical trial with its phosphodiesterase 4 inhibitor ELB353

Biotie has started a clinical trial with its phosphodiesterase 4 (PDE4) inhibitor ELB353, having received the prerequisite regulatory and ethical clearances for the clinical trial application.

14 Sep 2009

Phase 2b clinical trial results of Dextofisopam to treat irritable bowel syndrome announced

Pharmos Corporation (Pink Sheets: PARS) announced today the results of its Phase 2b Dextofisopam clinical trial to evaluate safety and efficacy of the compound in irritable bowel syndrome.

14 Sep 2009

Nervous System News and Research

Latest Nervous System News and Research

FDA approves Neuralstem's IND for commencing a stem cell trial to treat Amyotrophic Lateral Sclerosis

King Pharmaceuticals achieves milestone: Announces commercial availability of EMBEDA

Alcoholism may be dependent on IL-1 polymorphisms: Study

Wyeth and Ambrx collaborate to produce the next generation of biologic drugs

Biopharmaceutical company announces initial public offering

Nasdaq Stock Market issues deficiency letter to Neurobiological Technologies

Results from the BLOSSOM trial announced by Arena Pharmaceuticals

Rexahn to sign licensing and stock purchase agreements with Teva Pharmaceutical

FDA approves Valturna tablets for treating high blood pressure

KemPharm announces nomination of its second pipeline candidate

Phase 3 clinical study results of bazedoxifene released

Alvine Pharmaceuticals raises funds for Phase 2a clinical trial of its lead compound ALV003

Biocryst signs agreement with three partners to represent its anti-viral peramivir outside U.S.

Extension study data on Fampridine-SR drug

Alnylam and Medtronic announce pre-clinical research findings from their Huntington’s disease program

Neurologix to showcase novel gene transfer approach to Parkinson’s disease

Children with microcephaly should be screened for neurologic and cognitive problems, says guideline

Common pain cream could serve as cardiac-protectant during heart attack: Study

Biotie Therapies commences clinical trial with its phosphodiesterase 4 inhibitor ELB353

Phase 2b clinical trial results of Dextofisopam to treat irritable bowel syndrome announced

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Nervous System News and Research

Latest Nervous System News and Research

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Newsletters you may be interested in